X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to support HDT in advancing its next-generation vaccine HDT-521. Which is being evaluated in the preclinical trial studies for the treatment of prostate cancer.
Lead Product(s): HDT-521
Therapeutic Area: Oncology Product Name: HDT-521
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: BARDA
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Partnership January 23, 2024
Details:
The vaccine uses self-amplifying RNA (or “saRNA”), which replicates itself following administration and is thus effective at extremely low doses. In addition, it is stable at refrigerator temperatures—unlike current mRNA vaccines.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HDT-301
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
HDT301, an HDT Bio’s technology uses self-replicating RNA and has the potential to deliver a COVID-19 vaccine targeting multiple variants, providing broad protection from disease and reduced transmission from breakthrough infections.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HDT-301
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
Company RNA-based vaccine, HDT-301 (HGCO19) offers simpler manufacturing, greater stability, and vastly lower effective dosing than current mRNA COVID-19 vaccines.
Lead Product(s): HGCO19
Therapeutic Area: Infections and Infectious Diseases Product Name: HDT-301
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Quratis Co., Ltd
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2021
Details:
Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials.
Lead Product(s): HGCO19
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Recipient: Gennova Biopharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
This agreement will enable Quratis to manufacture HDT Bio's next-generation COVID-19 vaccine, HGCO19 and distribute it across much of East Asia.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase II/ Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Quratis Co., Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 16, 2021
Details:
HDT Bio has also developed HGCO19, a LION-based COVID-19 vaccine, in collaboration with Gennova Biopharmaceuticals of Pune, which is currently is being tested in India in a Phase 1/2 clinical trial.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Gennova Biopharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
Details:
HGCO19, is a novel mRNA vaccine candidate containing a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus, SARS-CoV-2, reported to interact with receptors on host cells.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2021
Details:
The Drugs Controller General of India (DCGI) has granted conditional permission for phases 1 and 2 human clinical trial of the COVID-19 vaccine candidate, HGCO19, developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA.
Lead Product(s): HGCO19
Therapeutic Area: Infections and Infectious Diseases Product Name: HGCO19
Highest Development Status: PreclinicalProduct Type: Vaccine
Recipient: Gennova Biopharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2020
Details:
Proceeds will be used largely to support continued development of the company’s COVID-19 vaccine candidate, HDT-301. The vaccine is slated to enter clinical trials in Q4 2020 in partnership with the NIH/NIAID.
Lead Product(s): HDT-301
Therapeutic Area: Infections and Infectious Diseases Product Name: HDT-301
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Zoic Capital
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
